FDA Finalizes Guidance on Vaginal Microbicides for HIV Prevention

Drug Industry Daily
Companies developing vaginal microbicide gels to prevent HIV infections should have a scoring system to measure the presence and severity of rash, swelling, immune response and damage to local tissue in human studies evaluating the safety and tolerability of the products, says a new final guidance.

To View This Article:


Subscribe To Drug Industry Daily